Ana de Barros, PhD, managing science editor —

Ana holds a PhD in immunology from the University of Lisbon and worked as a postdoctoral researcher at Instituto de Medicina Molecular (iMM) in Lisbon, Portugal. Ana was awarded two FCT fellowships and has won the Portuguese Immunology Society Best Paper and Best Poster award in 2009 and 2010, as well as the CESPU International Research Award in 2010. After leaving the lab to pursue a career in science communication, she served as the director of science communication at iMM Lisbon.

Articles by Ana de Barros

FDA Approves Austedo Tablets to Treat Movement Problems in Huntington’s

Teva Pharmaceutical Industries‘ Austedo tablets have received U.S. approval for treating chorea, or severe movement problems, associated with Huntington’s disease (HD). Austedo (deutetrabenazine, SD-809) is the first deuterated drug the U.S. Food and Drug Administration (FDA) has authorized, and only the second therapy it has approved for Huntington’s. The FDA had…

EU Calls for Research Proposals on Common Links in Neurodegenerative Diseases

The European Union is inviting researchers in 20 countries to work together on projects focusing on Huntington’s disease (HD) and other degenerative diseases. The agency sponsoring the effort, the Joint Programme — Neurodegenerative Disease Research (JPND), said in a press release that neurodegenerative conditions have become a global health epidemic, with heavy economic…

Critical Path Institute, CHDI Foundation Join Forces to Expedite Huntington’s Therapies

Critical Path Institute (C-Path) and CHDI Foundation have joined forces to create a consortium geared toward clearly defining regulatory pathways for faster approval of new Huntington’s disease (HD) treatments. The new HD Regulatory Science Consortium (HD-RSC) will gather participants from the Huntington’s disease community to expedite regulatory endorsement and to facilitate…